Fibronectin expression in carcinoma cells correlates with tumor aggressiveness and poor clinical outcome in patients with invasive breast cancer

Human Pathology

Volumn 44, Issue 10, 2013, Pages 2028-2037

  Bae, Young Kyung ^a   Kim, Aeri ^a   Kim, Min Kyoung ^a   Choi, Jung Eun ^a   Kang, Su Hwan ^a   Lee, Soo Jung ^a  

^a Yeungnam University College of Medicine   (South Korea)

Author keywords

Breast neoplasms; Fibronectin; Immunohistochemistry; Prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FIBRONECTIN; HORMONE RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PROTEIN EXPRESSION; SURVIVAL RATE; SURVIVAL TIME;

BREAST NEOPLASMS; FIBRONECTIN; IMMUNOHISTOCHEMISTRY; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; EPITHELIAL CELLS; FEMALE; FIBRONECTINS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM INVASIVENESS; REPUBLIC OF KOREA; STROMAL CELLS; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84884412852     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2013.03.006     Document Type: Article

References (28)

1. L. Christensen FN, laminin, and tetranectin in human breast cancer with special attention to the extracellular matrix APMIS Suppl 26 1992 1 39
2. E. Ioachim, A. Charchanti, and E. Briasoulis Immunohistochemical expression of extracellular matrix components tenascin, FN, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression Eur J Cancer 38 2002 2362 2370
3. S. Han, F.R. Khuri, and J. Roman FN stimulates non-small cell lung carcinoma cell growth through activation of akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways Cancer Res 66 2006 315 323
4. R. Korah, M. Boots, and R. Wieder Integrin alpha5beta1 promotes survival of growth-arrested breast cancer cells: an in vitro paradigm for breast cancer dormancy in bone marrow Cancer Res 64 2004 4514 4522
5. S. Vignot, S. Faivre, D. Aguirre, and E. Raymond mTOR-targeted therapy of cancer with rapamycin derivatives Ann Oncol 16 2005 525 537
6. S. Han, N. Sidell, S. Roser-Page, and J. Roman FN stimulates human lung carcinoma cell growth by inducing cyclooxygenase-2 (COX-2) expression Int J Cancer 11 2004 322 331
7. S. Han, N. Sidell, and J. Roman FN stimulates human lung carcinoma cell proliferation by suppressing p21 gene expression via signals involving erk and rho kinase Cancer Lett 219 2005 71 78
8. T. Kijima, G. Maulik, P.C. Ma, P. Madhiwala, E. Schaefer, and R. Salgia FN enhances viability and alters cytoskeletal functions (with effects on the phosphatidylinositol 3-kinase pathway) in small cell lung cancer J Cell Mol Med 7 2003 157 164
9. C. Foroni, M. Broggini, D. Generali, and G. Damia Epithelial-mesenchymal transition and breast cancer: role, molecular mechanisms and clinical impact Cancer Treat Rev 38 2012 689 697
10. C.O. Sung, C.K. Park, and S.H. Kim Classification of epithelial- mesenchymal transition phenotypes in esophageal squamous cell carcinoma is strongly associated with patient prognosis Mod Pathol 24 2011 1060 1068
11. J.Y. Han, H.S. Kim, S.H. Lee, W.S. Park, J.Y. Lee, and N.J. Yoo Immunohistochemical expression of integrins and extracellular matrix proteins in non-small cell lung cancer: correlation with lymph node metastasis Lung Cancer 41 2003 65 70
12. S. Ryu, S. Jimi, Y. Eura, T. Kato, and S. Takebayashi Retention of intracellular FN expression in primary and metastatic thyroid carcinoma: an immunohistochemical study Cancer Lett 133 1998 215 222
13. W. Gorczyca, R. Holm, and J.M. Nesland Laminin production and FN immunoreactivity in breast carcinomas Anticancer Res 13 1993 851 858
14. E. Ioachim, S. Kamina, M. Kontostolis, and N.J. Agnantis Immunohistochemical expression of cathepsin D in correlation with extracellular matrix component, steroid receptor status and proliferative indices in breast cancer Virchows Arch 431 1997 311 316
15. L. Christensen, M. Nielsen, J. Andersen, and I. Clemmensen Stromal FN staining pattern and metastasizing ability of human breast carcinoma Cancer Res 48 1988 6227 6233
16. A. Kim, H.C. Shin, and Y.K. Bae Multiplication of chromosome 17 centromere is associated with prognosis in patients with invasive breast cancers exhibiting normal HER2 and TOP2A status J Breast Cancer 15 2012 24 33
17. F.L. Greene, D.L. Page, and I.D. Fleming AJCC cancer staging manual 6th ed. 2002 Springer New York 347 376
18. C.W. Elston, and I.O. Ellis Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up Histopathology 19 1991 403 410
19. J.M. Kim, T.Y. Hwang, S.H. Kang, S.J. Lee, and Y.K. Bae Prognostic significance of basal markers in triple-negative breast cancers J Breast Cancer 12 2009 4 13
20. M.E. Hammond, D.F. Hayes, and M. Dowsett American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer J Clin Oncol 28 2010 2784 2795
21. A.C. Wolff, M.E. Hammond, and J.N. Schwartz American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol 25 2007 118 145
22. N. Hanamura, T. Yoshisa, E. Matsumoto, Y. Kawarada, and T. Sakakura Expression of FN and tenascin-C mRNA by myofibroblasts, vascular cells and epithelial cells in human colon adenomas and carcinomas Int J Cancer 73 1997 10 15
23. T. Yoshida, E. Matsumoto, and N. Hanamura Co-expression of tenascin and FN in epithelial and stromal cells of benign lesions and ductal carcinomas in the human breast J Pathol 182 1997 421 428
24. E.K. Rowinsky Targeting the molecular target of rapamycin (mTOR) Curr Opin Oncol 16 2004 564 575
25. R.A. Campbell, P. Bhat-Nakshatri, N.M. Patel, D. Constantinidou, S. Ali, and H. Nakshatri Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance J Biol Chem 276 2001 9817 9824
26. O.P. Kallioniemi, U. Wagner, J. Kononen, and G. Sauter Tissue microarray technology for high-throughput molecular profiling of cancer Hum Mol Genet 10 2001 657 662
27. R. Simon, and G. Sauter Tissue microarray (TMA) applications: implications for molecular medicine Expert Rev Mol Med 5 2003 1 12
28. T.A. Thomson, C. Zhou, K. Ceballos, and B. Knight Tissue microarray for routine clinical breast biomarker analysis. The British Columbia Cancer Agency 2008 experience Am J Clin Pathol 133 2010 909 914